US 11701355
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
granted A61KA61K31/216A61K31/41
Quick answer
US patent 11701355 (Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)) held by TENAX THERAPEUTICS, INC. expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TENAX THERAPEUTICS, INC.
- Grant date
- Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K31/216, A61K31/41, A61K31/495, A61K31/50